H. Yoshihara

发表

Therapeutic Strategies for Hepatocellular Carcinoma Based on Analyses for Resistance to Apoptosis Mediated by Activation of Intracellular Signal Pathways

N. Hayashi, T. Kamada, J. Wands, 2001 .

Hepatoma Cell Lines Fucosylation in Human Hepatocellular Carcinoma and forProduction of GDP-l-Fucose , a Common Donor Substrate Relationship between Elevated FX Expression and Increased Updated

N. Hayashi, A. Kasahara, J. Gu, 2003 .

Pretreatment viral load and response to interferon therapy for liver cirrhosis caused by hepatitis C virus: a multicenter controlled study

N. Hayashi, A. Kasahara, T. Kamada, 2000 .

Successful treatment of HCV-related cryoglobulinemic glomerulonephritis with double-filtration plasmapheresis and interferon combination therapy

Rie Shiba, H. Yoshihara, Yukinori Yamada, 2010, Clinical and Experimental Nephrology.

Renal dysfunction is an independent risk factor for bleeding after gastric ESD

Takuya Yamada, H. Ogiyama, Teppei Yoshioka, 2014, Endoscopy International Open.

Risk of non‐Hodgkin's lymphoma in patients with hepatitis C virus infection

H. Tsukuma, K. Aozasa, H. Yoshihara, 1999, International journal of cancer.

Expression of the c‐met protooncogene in human hepatocellular carcinoma

N. Hayashi, H. Fusamoto, T. Kamada, 1994, Hepatology.

The significance of interferon and ribavirin combination therapy followed by interferon monotherapy for patients with chronic hepatitis C in Japan.

N. Hayashi, A. Kasahara, N. Hiramatsu, 2004, Hepatology research : the official journal of the Japan Society of Hepatology.

Interrelationship between alcohol intake, hepatitis C, liver cirrhosis, and hepatocellular carcinoma.

T. Kamada, H. Yoshihara, K. Noda, 1998, Recent developments in alcoholism : an official publication of the American Medical Society on Alcoholism, the Research Society on Alcoholism, and the National Council on Alcoholism.

Circulating matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as serum markers of fibrosis in patients with chronic hepatitis C. Relationship to interferon response.

A. Kasahara, H. Fusamoto, A. Inoue, 1997, Journal of hepatology.

Stevens-Johnson syndrome induced by sorafenib for therapy of HCC: A case report

Teppei Yoshioka, H. Yoshihara, Yukinori Yamada, 2012 .

Long-term effect of lamivudine treatment on the incidence of hepatocellular carcinoma in patients with hepatitis B virus infection

Y. Imai, N. Hayashi, A. Kasahara, 2012, Journal of Gastroenterology.

Effect of interferon α‐2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with chronic hepatitis

Y. Imai, N. Hayashi, A. Kasahara, 2009, Hepatology research : the official journal of the Japan Society of Hepatology.

Declining Incidence of Hepatocellular Carcinoma in Osaka, Japan, from 1990 to 2003

H. Tsukuma, Y. Imai, N. Hayashi, 2008, Annals of Internal Medicine.

A patient with rheumatoid arthritis treated with tocilizumab together with lamivudine prophylaxis after remission of infliximab-reactivated hepatitis B

H. Yoshihara, K. Shi, H. Tsuboi, 2011, Modern rheumatology.

The impact of an inosine triphosphate pyrophosphatase genotype on bilirubin increase in chronic hepatitis C patients treated with simeprevir, pegylated interferon plus ribavirin

Y. Imai, N. Hayashi, N. Hiramatsu, 2016, Journal of Gastroenterology.

Factors affecting efficacy in patients with genotype 2 chronic hepatitis C treated by pegylated interferon alpha‐2b and ribavirin: reducing drug doses has no impact on rapid and sustained virological responses

Y. Imai, N. Hayashi, A. Kasahara, 2010, Journal of viral hepatitis.

Pegylated interferon alpha‐2b (Peg‐IFN α‐2b) affects early virologic response dose‐dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg‐IFN α‐2b plus ribavirin

Y. Imai, N. Hayashi, A. Kasahara, 2009, Journal of viral hepatitis.

Early decline of hemoglobin can predict progression of hemolytic anemia during pegylated interferon and ribavirin combination therapy in patients with chronic hepatitis C

Y. Imai, N. Hayashi, A. Kasahara, 2008, Hepatology research : the official journal of the Japan Society of Hepatology.

Progression of type C chronic hepatitis to liver cirrhosis and hepatocellular carcinoma--its relationship to alcohol drinking and the age of transfusion.

K. Suzuki, N. Hayashi, A. Kasahara, 1996, Alcoholism, clinical and experimental research.

Endothelial Growth Factor in Human Hepatocellular Carcinoma Expression of Vascular Permeability Factor / Vascular Updated

N. Hayashi, T. Kamada, Masato Yamamoto, 2006 .

Incidence of hepatocellular carcinoma in HCV-infected patients with normal alanine aminotransferase levels categorized by Japanese treatment guidelines

Y. Imai, N. Hayashi, A. Kasahara, 2013, Journal of Gastroenterology.

Ethanol‐induced vasoconstriction causes focal hepatocellular injury in the isolated perfused rat liver

H. Fusamoto, T. Kamada, Y. Takei, 1992, Hepatology.

Low Km ALDH isozyme and alcoholic liver injury

T. Kamada, H. Yoshihara, N. Sato, 1983, Pharmacology Biochemistry and Behavior.

Immunological response to interferon‐γ priming prior to interferon‐α treatment in refractory chronic hepatitis C in relation to viral clearance

N. Hayashi, Y. Sasaki, A. Kasahara, 2001 .

Significance of serum soluble Fas antigen level in chronic hepatitis C patients treated with interferon: Relationship to the therapeutic response

N. Hayashi, A. Kasahara, N. Hiramatsu, 2001, Journal of gastroenterology and hepatology.

Hepatic tissue oxygenation as a predictive indicator of ischemia‐reperfusion liver injury

H. Fusamoto, T. Kamada, Y. Takei, 1992, Hepatology.

Invariant natural killer T cell deficiency leads to the development of spontaneous liver inflammation dependent on γδT cells in mice

N. Hiramatsu, T. Kodama, Teppei Yoshioka, 2015, Journal of Gastroenterology.

Post-treatment levels of α-fetoprotein predict incidence of hepatocellular carcinoma after interferon therapy.

Y. Imai, N. Hayashi, A. Kasahara, 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Indications and limitations for aged patients with chronic hepatitis C in pegylated interferon alfa-2b plus ribavirin combination therapy.

Y. Imai, N. Hayashi, A. Kasahara, 2011, Journal of hepatology.

Ribavirin dose reduction raises relapse rate dose‐dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha‐2b plus ribavirin

Y. Imai, N. Hayashi, A. Kasahara, 2009, Journal of viral hepatitis.

Efficacy of re-treatment with pegylated interferon plus ribavirin combination therapy for patients with chronic hepatitis C in Japan

Y. Imai, N. Hayashi, A. Kasahara, 2011, Journal of Gastroenterology.

Impact of alpha-fetoprotein on hepatocellular carcinoma development during entecavir treatment of chronic hepatitis B virus infection

Y. Imai, N. Hayashi, A. Kasahara, 2015, Journal of Gastroenterology.

Initial viral response is the most powerful predictor of the emergence of YMDD mutant virus in chronic hepatitis B patients treated with lamivudine

Y. Imai, N. Hayashi, A. Kasahara, 2008, Hepatology Research.

Gene expression of α1‐6 fucosyltransferase in human hepatoma tissues: A possible implication for increased fucosylation of α‐fetoprotein

Naoyuki Taniguchi, Yoshitaka Ikeda, Eiji Miyoshi, 1998 .

IgG Oligosaccharide Alterations Are a Novel Diagnostic Marker for Disease Activity and the Clinical Course of Inflammatory Bowel Disease

N. Hayashi, T. Mizushima, H. Yoshihara, 2008, The American Journal of Gastroenterology.

Relationship between elevated FX expression and increased production of GDP-L-fucose, a common donor substrate for fucosylation in human hepatocellular carcinoma and hepatoma cell lines.

N. Hayashi, A. Kasahara, J. Gu, 2003, Cancer research.

A high expression of GDP-fucose transporter in hepatocellular carcinoma is a key factor for increases in fucosylation.

N. Hayashi, N. Taniguchi, H. Yoshihara, 2007, Glycobiology.

Lamivudine-to-entecavir switching treatment in type B chronic hepatitis patients without evidence of lamivudine resistance

Y. Imai, N. Hayashi, A. Kasahara, 2009, Journal of gastroenterology.

Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: A retrospective cohort study of 738 patients

A. Oshima, H. Tsukuma, N. Hayashi, 2000, International journal of cancer.

The real impact of telaprevir dosage on the antiviral and side effects of telaprevir, pegylated interferon and ribavirin therapy for chronic hepatitis C patients with HCV genotype 1

Y. Imai, N. Hayashi, A. Kasahara, 2015, Journal of viral hepatitis.

Factors contributing to antiviral effect of adefovir dipivoxil therapy added to ongoing lamivudine treatment in patients with lamivudine-resistant chronic hepatitis B

Y. Imai, N. Hayashi, A. Kasahara, 2009, Journal of Gastroenterology.

The prospective randomized study on telaprevir at 1500 or 2250 mg with pegylated interferon plus ribavirin in Japanese patients with HCV genotype 1

Y. Imai, N. Hayashi, A. Kasahara, 2015, Journal of Gastroenterology.

Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: A multicenter randomized controlled trial

N. Hayashi, A. Kasahara, H. Fusamoto, 1995, Hepatology.

Clinical efficacy and immunological effects of weekly administration of interferon-β in patients with type B chronic hepatitis

N. Hayashi, A. Kasahara, H. Fusamoto, 1999 .

Long-term biochemical and virological response to natural interferon-α in patients with chronic hepatitis C

N. Hayashi, A. Kasahara, H. Fusamoto, 1996, Digestive Diseases and Sciences.

Long‐term follow up of peginterferon‐α‐2a treatment of hepatitis B e‐antigen (HBeAg) positive and HBeAg negative chronic hepatitis B patients in phase II and III studies

H. Nomura, Y. Imai, Y. Karino, 2016, Hepatology research : the official journal of the Japan Society of Hepatology.

Early decline of hemoglobin correlates with progression of ribavirin-induced hemolytic anemia during interferon plus ribavirin combination therapy in patients with chronic hepatitis C

N. Hayashi, A. Kasahara, N. Hiramatsu, 2006, Journal of Gastroenterology.

The efficacy of extended treatment with pegylated interferon plus ribavirin in patients with HCV genotype 1 and slow virologic response in Japan

Y. Imai, N. Hayashi, A. Kasahara, 2011, Journal of Gastroenterology.

Present status of steroid administration to patients with autoimmune hepatitis and factors associated with relapse

Y. Imai, N. Hiramatsu, E. Morii, 2015 .

Randomized comparative study of omeprazole and famotidine in reflux esophagitis

H. Iishi, M. Tatsuta, H. Yoshihara, 2002, Journal of gastroenterology and hepatology.

Expression of vascular permeability factor/vascular endothelial growth factor in human hepatocellular carcinoma.

N. Hayashi, T. Kamada, Masato Yamamoto, 1996, Cancer research.

A CASE OF DIFFUSE CAVERNOUS HEMANGIOMA OF RECTUM IN WHICH FAT-SUPPRESSION MRI WAS USEFULFOR DIFFERENTIAL DIAGNOSISA CASE OF DIFFUSE CAVERNOUS HEMANGIOMA OF RECTUM IN WHICH FAT-SUPPRESSION MRI WAS USEFUL FOR DIFFERENTIAL DIAGNOSIS

T. Kamada, H. Yoshihara, K. Yoshikawa, 2008 .

Effect of acute and chronic ethanol consumption on hepatic tissue oxygen tension in rats

N. Hayashi, T. Kamada, H. Yoshihara, 1983, Pharmacology Biochemistry and Behavior.

Should aged patients with chronic hepatitis C be treated with interferon and ribavirin combination therapy?

N. Hayashi, A. Kasahara, N. Hiramatsu, 2006, Hepatology research : the official journal of the Japan Society of Hepatology.

Studies on alcoholic hepatic injuries-The first report pathological and angiological investigation to the false positive hepatic scan in patients with alcoholic liver cirrhosis

H. Yoshihara, Makoto Yamada, T. Matsumura, 2009 .

Reducing Peg-IFN doses causes later virologic response or no response in HCV genotype 1 patients treated with Peg-IFN alfa-2b plus ribavirin

Y. Imai, N. Hayashi, A. Kasahara, 2012, Journal of Gastroenterology.

Using early viral kinetics to predict antiviral outcome in response-guided pegylated interferon plus ribavirin therapy among patients with hepatitis C virus genotype 1

Y. Imai, N. Hayashi, A. Kasahara, 2014, Journal of Gastroenterology.

S100A8 Production in CXCR2-Expressing CD11b+Gr-1high Cells Aggravates Hepatitis in Mice Fed a High-Fat and High-Cholesterol Diet

Y. Imai, N. Hiramatsu, Teppei Yoshioka, 2016, The Journal of Immunology.

Risk factors for hepatocellular carcinoma in hepatitis C patients with normal alanine aminotransferase treated with pegylated interferon and ribavirin

Y. Imai, N. Hayashi, A. Kasahara, 2014, Journal of viral hepatitis.

Efficacy of pegylated interferon plus ribavirin combination therapy for hepatitis C patients with normal ALT levels: a matched case–control study

Y. Imai, N. Hayashi, A. Kasahara, 2011, Journal of Gastroenterology.

Effect of glycyrrhizin on viral replication and quasispecies in patients with type C chronic hepatitis

N. Hayashi, A. Kasahara, H. Fusamoto, 1997 .

Disease stage of chronic hepatitis C assessed by both peritoneoscopic and histologic findings and its relationship with response to interferon therapy.

N. Hayashi, A. Kasahara, H. Fusamoto, 1997, Gastrointestinal endoscopy.

Upregulation of GRAIL is associated with remission of ulcerative colitis.

N. Hayashi, H. Yoshihara, T. Kanto, 2008, American journal of physiology. Gastrointestinal and liver physiology.

Clinical use of molecular targeted agents for primary small bowel adenocarcinoma: A multicenter retrospective cohort study by the Osaka Gut Forum.

R. Ishihara, T. Takehara, H. Yoshihara, 2017, Oncology letters.

Gene expression of alpha1-6 fucosyltransferase in human hepatoma tissues: a possible implication for increased fucosylation of alpha-fetoprotein.

K. Suzuki, N. Hayashi, Y. Ikeda, 1998, Hepatology.

Complete clogging by fungus ball: a rare complication of gastrostomy.

H. Yoshihara, M. Komori, Shunsuke Yamamoto, 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Efficacy of interferon therapy in patients with chronic hepatitis C. Comparison between non-drinkers and drinkers.

H. Yoshihara, Kunio Suzuki, K. Kawano, 1994, Scandinavian journal of gastroenterology.

Abstracts of selected papers presented at the 75th General Meeting of the Japanese Society of Gastroenterology March 27–29, 1989 — Yokohama, Japan

A. Munakata, T. Matsui, T. Kamada, 2007, Gastroenterologia Japonica.

Y. Imai, A. Kasahara, N. Hiramatsu, 2009, Journal of viral hepatitis.

Impact of alpha-fetoprotein on hepatocellular carcinoma development during entecavir treatment of chronic hepatitis B virus infection

Y. Imai, N. Hayashi, A. Kasahara, 2015, Journal of Gastroenterology.

[Investigation of simplified international diagnostic criteria for autoimmune hepatitis].

Y. Imai, N. Hayashi, N. Hiramatsu, 2010, Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology.

Immunological response to interferon-gamma priming prior to interferon-alpha treatment in refractory chronic hepatitis C in relation to viral clearance.

N. Hayashi, A. Kasahara, T. Kamada, 2001, Journal of viral hepatitis.

A prospective study of hepatitis C virus infection after needlestick accidents.

N. Enomoto, H. Yoshihara, Y. Yamada, 2008, Liver.

Hepatic Hemodynamics In Rats Fed Ethanol Chronically Assessed By Organ-Reflectance Spectrophotometry And Hydrogen Clearance Method

Y. Sasaki, A. Kasahara, H. Fusamoto, 1984 .

Roles of endothelin-1 and nitric oxide in the mechanism for ethanol-induced vasoconstriction in rat liver.

H. Fusamoto, Y. Takei, H. Yoshihara, 1993, The Journal of clinical investigation.

Detection of nitric oxide production in lipopolysaccharide-treated rats by ESR using carbon monoxide hemoglobin.

H. Kosaka, H. Yoshihara, T. Shiga, 1992, Biochemical and biophysical research communications.